Physician profile
Brian E Abell
NPI 1215081534
$3,227.38
in general payments reported to CMS, 2019-2025
30 companies · $460 in 2025
The $460 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $206 · 2021: $697 · 2022: $338 · 2023: $787 · 2024: $458 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $783.80 | 2023-2025 | Evos, Trigen Intertan, Intellio Link Werewolf |
| Horizon Therapeutics Plc | $666.64 | 2019-2022 | |
| Depuy Synthes Sales INC. | $317.27 | 2020-2025 | Tfn-Advance, Orthovisc, Monovisc |
| Stryker Corporation | $261.66 | 2021-2023 | Augment Injectable |
| Zimmer Biomet Holdings, INC. | $200.29 | 2019-2023 | Comprehensive Shoulder System |
| Organogenesis INC. | $121.07 | 2021-2025 | Cygnus Dual, Simplimax, Via Matrix |
| Fidia Pharma USA INC. | $115.23 | 2023 | Hymovis, Triluron |
| Aap Implants INC | $106.00 | 2021 | |
| Bsn Medical INC | $93.50 | 2019 | |
| Innovation Technologies INC | $64.42 | 2023-2025 | Irrisept |
| Ortho Solutions INC | $54.50 | 2024 | |
| Convatec INC. | $45.46 | 2020-2024 | |
| Davol INC. | $41.59 | 2025 | Arista |
| Vertex Pharmaceuticals Incorporated | $40.65 | 2025 | |
| Boston Scientific Corporation | $38.58 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $30.90 | 2025 | |
| Acelrx Pharmaceuticals, INC. | $26.94 | 2019-2021 | |
| Trice Medical, INC. | $24.05 | 2019 | |
| Vericel Corporation | $21.38 | 2024 | Maci |
| Heron Therapeutics, INC. | $21.06 | 2021 | |
| Linvatec Corporation | $19.26 | 2025 | 5ms |
| Abbvie INC. | $18.12 | 2023 | Dalvance |
| Avanos Medical | $16.38 | 2024 | Trivisc Sodium Hyaluronate |
| Abbott Laboratories | $15.94 | 2022 | |
| Amgen INC. | $15.24 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2022 | |
| Orthogenrx INC. | $14.39 | 2019 | |
| Medtronic, INC. | $11.81 | 2022 | |
| Dynasplint Systems INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Abell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.